Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says

Patient Death in Phase 2b Prostate Cancer Trial Unrelated to Topsalysin, Sophiris Says
Topsalysin (PRX302), an investigative agent for localized prostate cancer, is unlikely to have caused the death of a patient in a Phase 2b trial testing the medicine, Sophiris Bio announced. A review of clinical records and information from the autopsy point to a sudden cardiac event caused by an arrhythmia as the most likely cause of death; the patient

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *